KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other financing activities: 2009-2023

Historic Other financing activities for Alnylam Pharmaceuticals (ALNY) over the last 13 years, with Dec 2023 value amounting to $24.7 million.

  • Alnylam Pharmaceuticals' Other financing activities fell 121.24% to -$1.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $8.3 million, marking a year-over-year decrease of 65.03%. This contributed to the annual value of $24.7 million for FY2023, which is 20.43% down from last year.
  • According to the latest figures from FY2023, Alnylam Pharmaceuticals' Other financing activities is $24.7 million, which was down 20.43% from $31.0 million recorded in FY2022.
  • In the past 5 years, Alnylam Pharmaceuticals' Other financing activities registered a high of $31.0 million during FY2022, and its lowest value of $8.4 million during FY2020.
  • Its 3-year average for Other financing activities is $25.1 million, with a median of $24.7 million in 2023.
  • In the last 5 years, Alnylam Pharmaceuticals' Other financing activities surged by 133.33% in 2021 and then fell by 20.43% in 2023.
  • Yearly analysis of 4 years shows Alnylam Pharmaceuticals' Other financing activities stood at $8.4 million in 2020, then soared by 133.33% to $19.6 million in 2021, then soared by 58.16% to $31.0 million in 2022, then dropped by 20.43% to $24.7 million in 2023.